# The Combination of Thymoquinone and Chloroquine Dose-Dependently Regulates Autophagy and Potentiates Metastatic Melanoma Cell Death via Autophagy-Dependent and -Independent Mechanisms

**Authors:** Patrycja Kłos, Krzysztof Safranow, Magdalena Perużyńska, Radosław Birger, Agata Stępniewska, Violetta Dziedziejko, Marek Droździk, Dariusz Chlubek

PMC · DOI: 10.3390/ijms27041751 · International Journal of Molecular Sciences · 2026-02-11

## TL;DR

Combining thymoquinone and chloroquine increases cancer cell death in melanoma by affecting autophagy, a process cells use to survive stress.

## Contribution

This study reveals how thymoquinone and chloroquine interact to enhance melanoma cell death through both autophagy-dependent and -independent mechanisms.

## Key findings

- The combination of thymoquinone and chloroquine showed additive or sub-additive cytotoxic effects in melanoma cell lines.
- Thymoquinone increased autophagosome accumulation in WM9 cells while reducing chloroquine's anti-autophagic effect.
- The drug combination altered cell morphology and autophagy dynamics in metastatic melanoma cells.

## Abstract

Although combination therapies with mitogen activated protein kinase inhibitors remain among the most effective treatments for malignant melanoma, they are not universally applicable to all subtypes of this cancer, and their efficacy decreases in the presence of distant metastases. Drug resistance, often associated with elevated autophagy in tumor cells, and adverse effects of the treatment also reduce the survival time of melanoma patients. Therefore, the aim of our research was to assess the cytotoxicity of the combination of a late-stage autophagy blocker chloroquine with thymoquinone, a natural substance with anticancer potential and low toxicity towards healthy cells, in metastatic melanoma cell lines. Using the WST-1 assay, we examined the cytotoxicity of the combination of chloroquine and thymoquinone in melanoma WM9 and WM852 cell lines and assessed the type of their interactions. Additionally, using time-lapse bright field and fluorescent microscopy, we assessed changes in cell morphology during 48 h incubation with the tested compounds and their combinations, as well as their effect on autophagy. We identified an additive and sub-additive cytotoxic effect of thymoquinone/chloroquine combinations against WM9 and WM852 cells. Moreover, we found that thymoquinone combined with chloroquine caused an increase in autophagosome accumulation in WM9 cells, while attenuating the chloroquine’s anti-autophagic effect. A thorough understanding of the mechanism of drug interactions with natural substances is crucial for the development of new effective anticancer therapies.

## Linked entities

- **Chemicals:** thymoquinone (PubChem CID 10281), chloroquine (PubChem CID 2719)
- **Diseases:** malignant melanoma (MONDO:0005105), melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, BBC3 (BCL2 binding component 3) [NCBI Gene 27113] {aka JFY-1, JFY1, PUMA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** hypertension (MESH:D006973), colon cancer (MESH:D015179), metastases (MESH:D009362), Cytotoxicity (MESH:D064420), breast cancer (MESH:D001943), glioblastoma (MESH:D005909), mitochondrial damage (MESH:D028361), inflammation (MESH:D007249), injury to (MESH:D014947), Melanoma (MESH:D008545), metastatic (MESH:D000092182), asthma (MESH:D001249), cancer (MESH:D009369), chronic obstructive pulmonary disease (MESH:D029424), hypoxic (MESH:D002534), skin cancer (MESH:D012878), gastric cancer (MESH:D013274), non-small cell and small cell lung cancer (MESH:D002289)
- **Chemicals:** doxorubicin (MESH:D004317), hydroxychloroquine (MESH:D006886), carboplatin (MESH:D016190), penicillin (MESH:D010406), TQ (MESH:C003466), TQ20 (-), cisplatin (MESH:D002945), monoterpenoid (MESH:D039821), pembrolizumab (MESH:C582435), Hoechst 33342 (MESH:C017807), dabrafenib (MESH:C561627), ATP (MESH:D000255), L-glutamine (MESH:D005973), CO2 (MESH:D002245), DMSO (MESH:D004121), DAPI (MESH:C007293), docetaxel (MESH:D000077143), reactive oxygen species (MESH:D017382), CQ (MESH:D002738), Cy5 (MESH:C085321), gemcitabine (MESH:D000093542), nivolumab (MESH:D000077594), benzoquinone (MESH:C004532), oxygen (MESH:D010100), quinones (MESH:D011809), binimetinib (MESH:C581313), cabazitaxel (MESH:C552428), streptomycin (MESH:D013307), vemurafenib (MESH:D000077484), cobimetinib (MESH:C574276), ferulic acid (MESH:C004999), trametinib (MESH:C560077), encorafenib (MESH:C000601108), water (MESH:D014867), 5-fluorouracil (MESH:D005472), Chloroquine diphosphate (MESH:C023676), cyclophosphamide (MESH:D003520), resveratrol (MESH:D000077185), ipilimumab (MESH:D000074324)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** valine-to-glutamic acid, V600
- **Cell lines:** A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), Mel624 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_8054), WM852 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_6804), SK-Mel-2 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_0069), DM6 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_6628), WM9 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_6806), MW852 cell line — Homo sapiens (Human), Gaucher disease, Finite cell line (CVCL_8515)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941083/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941083/full.md

## References

75 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941083/full.md

---
Source: https://tomesphere.com/paper/PMC12941083